Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Buffer ⢠Persistent Cash Burn ⢠Equity Dilution PHVS offers strong cash liquidity and low leverage, but its high cash burn, absent revenue, recurring losses, and equity-driven dilution make it a high-risk, commercialization-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Volatile consolidation ⢠Weakening momentum ⢠Key breakout level Support Level: $35.30â$34.60 Resistance Level: $38.00â$38.90 PHVS was volatile but directionless last month; holding above $35.30 is key, while a break above $38.90 would restore bullish momentum.
Sentiment & News
Key News Insights: ⢠Phase 3 success ⢠83% attack reduction ⢠Mixed investor flows Pharvaris' strong Phase 3 CHAPTER-3 results and planned 2027 filings bolster its growth outlook despite mixed institutional and insider trading activity.
AI Summary
PHVS is now a clinically de-risked but commercially unproven oral HAE franchise: CHAPTER-3's 83% attack reduction creates meaningful upside into 2027 FDA and filing catalysts, but investors should require evidence of approval, payer access, and adoption before underwriting sustained value given ongoing cash burn and dilution risk.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |